Clinical trials: Infusions, Intravenous
Gout, Hyperuricemia
Safety and Efficacy Study of Intravenous Uricase-PEG 20
The purpose of this study is to assess the safety, pharmacokinetics and pharmacodynamics of single intravenous doses of Uricase-PEG 20.
- Trial name
- NCT01021241
- Testing
- Uricase-PEG 20
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- EnzymeRx
Invasive Candidiasis
Evaluate Bioequivalence of Micafungin (50mg/Vial)
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of micafungin (50 mg/vial) after intravenous infusion of 50 mg micafungin in healthy volunteers under fasting conditions
- Trial name
- NCT05496725
- Testing
- Micafungin
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Heparin
Study With Heparin Sodium in Intravenous Administration
The purpose of this phase I study is to know the pharmacodynamic profile in in intravenous application in humans of the sodium heparin of porcine origin of the company União Química, building from the pharmacodynamic data…
- Trial name
- NCT03125187
- Testing
- Sodium heparin UQ Intravenous drug administration, Sodium heparin FK Intravenous drug administration
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- União Química Farmacêutica Nacional S/A
Pharmacokinetics
Hutrukin to Analyze Safety and PK in Healthy Volunteers
The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).
- Trial name
- NCT05098080
- Testing
- Hutrukin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- XBiotech, Inc.
Healthy
A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)
The purpose of this study is to determine approximately what percentage of an orally administered dose of PD-0332991 is absorbed from the gastrointestinal tract into the systemic circulation.
- Trial name
- NCT01802476
- Testing
- Oral Drug Formulation of PD-0332991, Intravenous Formulation of PD-0332991
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Ghrelin Decreases Insulin Sensitivity
Ghrelin administration increases appetite and, in rodents, induces weight gain. The aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.
- Trial name
- NCT00512525
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Sedation
Intravenous Infusion of Lidocaine in Colonoscopy
intravenous infusion of lidocaine significantly reduce fatigue and pain and improve the patients satisfaction after sedation for colonoscopy.
- Trial name
- NCT04439786
- Testing
- lidocaine
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shandong University
Postpartum Hemorrhage
Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress
Patients having Cesarean section after they have been in labor for many hours bleed much more, in average twice as much, as compared with patients having an elective Cesarean section.
- Trial name
- NCT01869556
- Testing
- Oxytocin, Ergot, Carboprost
- Where
- Canada
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Healthy
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
This is a randomized, placebo controlled, single dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-E2 in healthy male subjects.
- Trial name
- GX-E2-P1 (NCT02291991)
- Testing
- GX-E2
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants
The purpose of this study is to assess the safety and tolerability of guselkumab following single-dose intravenous (IV) infusion in Japanese healthy male participants.
- Trial name
- NCT03536325
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Healthy
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers
Study to assess safety, tolerability and pharmacokinetics (PK) of single intravenous (i.v.) doses of BIIB 722 CL
- Trial name
- NCT02224079
- Testing
- BIIB 722 CL
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Decompensation, Acute
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is no formal hypothesis to be statistically tested.
- Trial name
- NCT02932969
- Testing
- BMS-986231
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Total Knee Arthroplasty
Vancomycin in TKAs
Periprosthetic joint infection (PJI) is a national health crisis and leads to very poor outcomes for patients undergoing elective joint replacement.
- Trial name
- NCT07282782
- Testing
- Vancomycin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Healthy
Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects
Study to assess the tolerability of an intravenous infusion of 0.5 and 1.0 mg (actual 0.8 mg) BIBT 986 BS per hour over 32 hours as well as pharmacokinetics and the effect on blood coagulation parameters
- Trial name
- NCT02254083
- Testing
- BIBT 986 BS - low, BIBT 986 BS - high
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction, Myocardial Ischemia
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
The purpose of this study is to determine whether the intravenous administration of single- and multiple-ascending doses of Thymosin Beta 4 is safe and tolerable in healthy volunteers.
- Trial name
- NCT00743769
- Testing
- thymosin beta 4
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Healthy
A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects
This is a randomized, double-blind, placebo-controlled, dose-increasing Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous infusion of LPM3480392 injection…
- Trial name
- NCT05862974
- Testing
- LPM3480392
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.
- Trial name
- NCT03500627
- Testing
- OP-101
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Orpheris, Inc.
Healthy
A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.
- Trial name
- NCT05515588
- Testing
- BI 690517 (C-14), BI 690517
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers
Safety, tolerability and pharmacokinetics of BIII 890
- Trial name
- NCT02269215
- Testing
- BIII 890 CL
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim